Sign In
Buy FBLG
$1.07
+0.0200 (+1.90%)
At Close: Jun 03, 2026
FibroBiologics Announces $25 Million Financing
07:55am, Monday, 23'rd Dec 2024
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the dev
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
09:15am, Tuesday, 19'th Nov 2024
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeu
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the devel
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04:20pm, Tuesday, 12'th Nov 2024
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
09:15am, Tuesday, 29'th Oct 2024
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
09:31am, Monday, 28'th Oct 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the d
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
08:30am, Friday, 18'th Oct 2024
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, developmen
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
09:15am, Wednesday, 16'th Oct 2024
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the deve
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
09:31am, Friday, 11'th Oct 2024
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the d
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
09:31am, Monday, 30'th Sep 2024
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care program
FibroBiologics Engages Southern Star Research as CRO in Australia
09:31am, Thursday, 19'th Sep 2024
Southern Star Research will provide CRO services for FibroBiologics in Australia Southern Star Research will provide CRO services for FibroBiologics in Australia
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09:31am, Friday, 06'th Sep 2024
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the d
FibroBiologics Files 2024 Second Quarter Report
06:52pm, Wednesday, 07'th Aug 2024
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development o
